In this insightful interview, Dr Veronica J. Brady, 2025 President of the Association of Diabetes Care & Education Specialists (ADCES), speaks about the organization’s mission to empower diabetes care and education specialists and improve patient outcomes. Dr Brady discusses the ...

Women & Diabetes takes centre stage in this interview with Zeina Abou Rizk, Founder of DiaLeb. Zeina explores the unique challenges women face in diabetes care, the power of community and advocacy, and how DiaLeb’s annual panel fosters global awareness, education, and meaningful change through lived experiences and expert insights.

Diabetes is a chronic disease associated with both acute and chronic complications. Many advances have been introduced throughout history to address these problems. While each clinical breakthrough was welcomed with relief and the expectation that a solution had been discovered, ...

The prevalence of diabetes during pregnancy is rapidly increasing. In the USA alone, an estimated 1–2% of pregnant women have type 1 diabetes (T1D) or type 2 diabetes (T2D), and an additional 6–9% develop gestational diabetes.1 From 2000 to 2010, the prevalence of gestational ...

Welcome to the latest edition of touchREVIEWS in Endocrinology, which features a range of review, case report and original research articles that highlight some key developments in our understanding and management of endocrinological disease. We begin with a commentary from ...

Gestational diabetes mellitus (GDM) is generally defined as “any degree of glucose tolerance with onset or first recognition during pregnancy”.1 It currently is one of the diseases with the highest morbidity among pregnant women.2 Determining its prevalence has been a ...

There has been an exponential increase in the global prevalence of obesity over the past few decades because of adverse lifestyle choices, such as physical inactivity and overconsumption of macronutrients. The obesity pandemic has contributed to more than 50 different disorders ...

Highlights Enhanced external counterpulsation (EECP) is evaluated for glycaemic control in type 2 diabetes. Glycated haemoglobin reduction immediately after EECP therapy conclusion, after 2–4 weeks and after 7–12 weeks was -0.70%, 1.04% and 0.98%, respectively. EECP is associated with a significant lowering of blood pressure. ...